Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (h CMV ). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on h CMV envelope. Fiztasovimab inhibits cell-to-cell transmission of h CMV. In Vitro Fiztasovimab is isolated from Epstein-Barr virus-transformed peripheral B cells of a healthy donor. Fiztasovimab has a broadly neutralizing activity against 4 laboratory strains (AD169, Towne, Davis, Merlin) and 42 Japanese clinical isolates, which included GCV-resistant isolates. Fiztasovimab shows anti-hMCV activities in MRC-5 human embryonic fibroblast cells and human adult retinal pigment epithelial cells with IC 50 s of 13-105 ng/mL and IC 90 s of 0.208-1.026 μg/mL. Fiztasovimab also inhibits cell-to-cell infection by hCMV isolates in adult retinal pigment epithelial cells with IC90s of 13-19 μg/mL. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Fiztasovimab
CAS number：2467411-25-0 molecular formula：
overview
compound introduction
Specs
| Chinese alias | 菲兹他索维马 | ||
| English alias | - | ||
| CAS number | 2467411-25-0 | molecular formula | |
| molecular weight | - | Exact mass | - |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
